Fibralign, Inc., a Union City CA-based maker of therapeutic medical devices for regenerative medicine, raised funding from a syndicate of AngelMD, an investment and networking platform connecting innovative medical startups, physicians, investors, and industry partners.
The amount of the deal was not disclosed.
Led by Greg King, CEO, Fibralign leverages patented Nanoweave® 3D scaffolding technology to make regenerative medicine solutions. The company’s first product, BioBridge®, directly addresses an area of concern for cancer and cosmetic surgery patients who suffer from secondary lymphedema.
Beyond its initial market, BioBridge also has significant follow-on opportunities for treating ischemia, cell/drug delivery, and gene therapy (mmRNA).
Fibralign has a team that consist of eight full-time and seven part-time members whose deep experience span across biotech, engineering, materials science, operations, process development and market/business development.